CD8A and neoplasm: In a tumor-bearing mouse model, the combination of the glycolysis inhibitor FX-11 and PD-1 monoclonal antibody significantly increased the infiltration of CD8+ T cells and NK cells in MPS2 tumors, effectively slowing their growth, whereas no significant effects were observed in MPS1 and MPS3 tumors (43) (Figure 2).